TIDMHIK

RNS Number : 9221Q

Hikma Pharmaceuticals Plc

02 March 2021

Notification and public disclosure of transactions by persons discharging managerial responsibilities

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                      Douglas Hurt 
 2    Reason for the notification 
 a)   Position/status           Non-Executive Director 
 b)   Initial notification      Initial notification 
       /Amendment 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 a)   Name                      Hikma Pharmaceuticals PLC 
 b)   LEI                       549300BNS685UXH4JI75 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
 a)   Description of            Description: Ordinary shares of 10 pence each 
       the financial             (Shares) 
       instrument, type          ID Code: GB00B0LCW083 
       of instrument 
       and identification 
       code 
 b)   Nature of the             Market purchase of 1,500 Ordinary Shares by 
       transaction               Gillian Hurt, spouse of Douglas Hurt 
 c)   Price(s) and              Price(s): GBP22.65 
       volume(s)                 Volume(s): 1,500 
 d)   Aggregated information 
        *    Volume              1,500 
                                 GBP22.65 
                                 GBP33,975 
        *    Price 
 
 
        *    Total 
 e)   Date of the transaction   2 March 2021 
 f)   Place of the              London Stock Exchange (XLON) 
       transaction

Peter Speirs

Company Secretary, responsible for releasing this announcement

+44 (0) 20 7399 2760

2 March 2021

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBLGDXXSGDGBD

(END) Dow Jones Newswires

March 02, 2021 11:44 ET (16:44 GMT)

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Hikma Pharmaceuticals
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Hikma Pharmaceuticals